Revolution Medicines, Inc. 完成总额20亿美元普通股及可转换优先票据同步增发定价

美股速递
Apr 15

生物制药公司Revolution Medicines, Inc. 已成功为其同步进行的增发交易完成定价,此次发行包括普通股及可转换优先票据,募集资金总额高达20亿美元。该交易规模较最初计划有所扩大,显示出市场对其融资方案的强劲需求。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10